Prime Medicine (PRME) Accounts Payables (2021 - 2026)
Prime Medicine (PRME) posted Accounts Payables of $12.3 million for Q1 2026, up 38.69% on a QoQ basis from $8.9 million in Q4 2025, and up 22.94% year-over-year from $10.0 million in Q1 2025.
Prime Medicine (PRME) Accounts Payables (2021 - 2026) Analysis & Trends
Prime Medicine's Accounts Payables history runs 6 years deep, the most recent figure standing at $12.3 million for Q1 2026.
- Quarterly Accounts Payables rose 22.94% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 22.94% YoY) and the FY2025 annual result came in at $8.9 million, down 21.71% from the prior year.
- Accounts Payables was $12.3 million for Q1 2026 at Prime Medicine, up from $8.9 million in the prior quarter.
- Across five years, Accounts Payables topped out at $19.5 million in Q4 2023 and bottomed at $4.1 million in Q3 2022.
- A 5-year average of $8.7 million and a median of $8.9 million in 2025 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables soared 350.99% — and 2024, when it sank 61.56%.
- Prime Medicine's Accounts Payables stood at $4.3 million in 2022, then surged by 350.99% to $19.5 million in 2023, then plunged by 41.9% to $11.4 million in 2024, then slipped by 21.71% to $8.9 million in 2025, then soared by 38.69% to $12.3 million in 2026.
- Business Quant data shows PRME's Accounts Payables at $12.3 million in Q1 2026, $8.9 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Prime Medicine | 525.98 Mn | 525.98 Mn | - | 12.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.33 Mn |
| Dec 31, 2025 | 8.89 Mn |
| Sep 30, 2025 | 9.35 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Mar 31, 2025 | 10.03 Mn |
| Dec 31, 2024 | 11.35 Mn |
| Sep 30, 2024 | 5.43 Mn |
| Jun 30, 2024 | 4.64 Mn |
| Mar 31, 2024 | 10.08 Mn |
| Dec 31, 2023 | 19.54 Mn |
| Sep 30, 2023 | 14.12 Mn |
| Jun 30, 2023 | 5.49 Mn |
| Mar 31, 2023 | 4.56 Mn |
| Dec 31, 2022 | 4.33 Mn |
| Sep 30, 2022 | 4.11 Mn |
| Dec 31, 2021 | 1.44 Mn |